Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata

References

• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ1194
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–1456. doi: 10.1056/NEJMra1315399
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–163. doi: 10.1128/CMR.00029-06
   PubMed Web of Science ®Google Scholar
• Whaley SG, Rogers PD. Azole resistance in Candida glabrata. Curr Infect Dis Rep. 2016;18(12):41. doi: 10.1007/s11908-016-0554-5
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–1732. doi: 10.1093/cid/cit136
   PubMed Web of Science ®Google Scholar
• Pham CD, Iqbal N, Bolden CB, et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58(8):4690–4696. doi: 10.1128/AAC.03255-14
   PubMed Web of Science ®Google Scholar
• Hou X, Xiao M, Chen SC, et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study. Front Microbiol. 2017;8(880):1–9.
   PubMedGoogle Scholar
• Xiao M, Fan X, Hou X, et al. Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant Candida tropicalis and Candida glabrata isolates with delineation of their resistance mechanisms. Infect Drug Resist. 2018;11:155–161. doi: 10.2147/IDR.S152785
   PubMed Web of Science ®Google Scholar
• Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci. 2015;1354(1):1–11. doi: 10.1111/nyas.12831
   PubMed Web of Science ®Google Scholar
• Kitada K, Yamaguchi E, Arisawa M. Cloning of the Candida glabrata TRP1 and HIS3 genes, and construction of their disruptant strains by sequential integrative transformation. Gene. 1995;165(2):203–206. doi: 10.1016/0378-1119(95)00552-H
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Alastruey-Izquierdo A, Healey KR, et al. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother. 2012;56(12):6304–6309. doi: 10.1128/AAC.00813-12
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI, Wayne, PA, USA. 2017.
   Google Scholar
• Grahl N, Demers EG, Crocker AW, et al. Use of RNA-protein complexes for genome editing in non-albicans Candida species. mSphere. 2017;2(3):e00218-17. doi: 10.1128/mSphere.00218-17
   PubMed Web of Science ®Google Scholar
• Istel F, Schwarzmuller T, Tscherner M, et al. Genetic transformation of Candida glabrata by electroporation. Bio Protoc. 2015;5(14):1–5.
   Google Scholar
• Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp isolates. Antimicrob Agents Chemother. 2005;49(8):3264–3273. doi: 10.1128/AAC.49.8.3264-3273.2005
   PubMed Web of Science ®Google Scholar
• Li QQ, Skinner J, Bennett JE. Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment. BMC Mol Biol. 2012;13(22):1–13.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Andes D. Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol Med. 2005;118:111–128.
   PubMedGoogle Scholar
• Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303–306. doi: 10.4103/0976-500X.119726
   PubMedGoogle Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10. doi: 10.1111/1469-0691.12539
   Web of Science ®Google Scholar
• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392. doi: 10.1016/S1473-3099(17)30316-X
   PubMed Web of Science ®Google Scholar
• Niimi K, Woods MA, Maki K, et al. Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression. J Antimicrob Chemother. 2012;67(7):1666–1676. doi: 10.1093/jac/dks112
   PubMed Web of Science ®Google Scholar
• Bizerra FC, Jimenez-Ortigosa C, Souza ACR, et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother. 2014;58(4):2438–2440. doi: 10.1128/AAC.02189-13
   PubMed Web of Science ®Google Scholar
• Magill SS, Swoboda SM, Shields CE, et al. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg. 2009;249(4):657–665. doi: 10.1097/SLA.0b013e31819ed914
   PubMed Web of Science ®Google Scholar
• Cheng SJ, Clancy CJ, Hartman DJ, et al. Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infect Immun. 2014;82(7):3015–3022. doi: 10.1128/IAI.00062-14
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20(11):1833–1840. doi: 10.3201/eid2011.140685
   PubMed Web of Science ®Google Scholar